Sign In
Buy ADVM
$4.36
+0 (+0%)
At Close: Mar 06, 2026
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 28'th Feb 2025
REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement
Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference
07:00am, Tuesday, 25'th Feb 2025
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly p
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:05pm, Wednesday, 05'th Feb 2025
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly p
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 06'th Dec 2024
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on December 4, 2024, the Compensation Committee of Adverum's Board of Director
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 20'th Nov 2024
REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum's Board of Directo
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
01:37pm, Monday, 18'th Nov 2024
Adverum Biotechnologies, Inc. achieved positive results from both the LUNA and OPTIC studies, using Ixo-vec for the treatment of patients with wet age-related macular degeneration. The phase 3 ARTEMIS
– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18 th at 7:30 a.m. EST
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
07:01pm, Monday, 04'th Nov 2024
Adverum Biotechnologies (ADVM) came out with a quarterly loss of $1.30 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $3.30 per share a year ago.
- 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
08:00am, Wednesday, 16'th Oct 2024
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:01pm, Friday, 11'th Oct 2024
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term
Bet on 5 Top-Ranked Stocks With Rising P/E
05:30am, Wednesday, 02'nd Oct 2024
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Adverum Biotechnologies (ADVM), IceCure Medical (ICCM), DarioHealth (DRIO), Energous (WATT) and V
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Thursday, 05'th Sep 2024
REDWOOD CITY, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on September 3, 2024, the Compensation Committee of Adverum's Board of Direct
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
04:05pm, Wednesday, 04'th Sep 2024
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?
10:55am, Tuesday, 03'rd Sep 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 332.3% in Adverum Biotechnologies (ADVM). While the effectiveness of this highly sought-after metric is questio
